CVS Health has upgraded its full-year 2025 financial guidance, citing stronger-than-expected performance across its pharmacy, retail, and health services segments. The company anticipates continued momentum into 2026, projecting a year-over-year profit growth.
- CVS Health raised 2025 adjusted EPS guidance to $10.45–$10.55, up from $10.05–$10.25
- 2025 revenue forecast now at $348 billion, $12 billion higher than prior outlook
- 2026 adjusted EPS projected at $11.30–$11.50, indicating 7.5%–9.5% growth
- Pharmacy services revenue rose 5.8% YoY; retail same-store sales up 4.3%
- Health services segment saw 7.2% increase in patient visits
- Plan to return $6.8 billion to shareholders via dividends and buybacks
CVS Health Corp. has raised its full-year 2025 adjusted earnings forecast to a range of $10.45 to $10.55 per share, up from its previous guidance of $10.05 to $10.25 per share. This revision reflects improved operational execution and sustained demand in its pharmacy benefit management (PBM) and retail pharmacy divisions. The company also reported that its 2025 revenue is expected to reach $348 billion, a $12 billion increase from earlier projections. The upward revision underscores strong performance in key business lines, including a 5.8% year-over-year growth in pharmacy services revenue and a 4.3% rise in retail pharmacy same-store sales. Additionally, the company's health services segment, which includes MinuteClinic and Caremark, recorded a 7.2% increase in patient visits, contributing to margin expansion. These results are attributed to expanded provider networks, enhanced digital engagement tools, and strategic pricing adjustments. Looking ahead, CVS Health projects adjusted earnings per share of $11.30 to $11.50 for 2026, signaling a 7.5% to 9.5% growth compared to the revised 2025 outlook. This forecast reflects confidence in the scalability of its integrated care model and continued investment in value-based health programs. The company also plans to return $6.8 billion to shareholders through dividends and share repurchases over the next 12 months. The guidance update has prompted positive reactions in the market, with CVS Health's stock rising 2.3% in pre-market trading. Investors are particularly focused on the company's ability to maintain profitability amid ongoing regulatory scrutiny and inflationary pressures. Analysts note that the improved outlook could influence broader healthcare sector sentiment, especially among integrated health providers.